Circulating tumor DNA predicts neoadjuvant immunotherapy efficacy and recurrence-free survival in surgical non-small cell lung cancer patients

BACKGROUND: There is currently a lack of effective biomarkers to evaluate efficacy of neoadjuvant therapy (NAT) for resectable non-small cell lung cancer (NSCLC) patients. Circulating tumor DNA (ctDNA) has been investigated as a non-invasive tool for the assessment of tumor burden and minimal residu...

Descripción completa

Detalles Bibliográficos
Autores principales: Yue, Dongsheng, Liu, Weiran, Chen, Chen, Zhang, Tao, Ma, Yuchen, Cui, Longgang, Gu, Yajun, Bei, Ting, Zhao, Xiaochen, Zhang, Bei, Bai, Yuezong, Romero, Atocha, Xu-Welliver, Meng, Wang, Changli, Zhang, Zhenfa, Zhang, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902085/
https://www.ncbi.nlm.nih.gov/pubmed/35280315
http://dx.doi.org/10.21037/tlcr-22-106

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902085/
https://www.ncbi.nlm.nih.gov/pubmed/35280315
http://dx.doi.org/10.21037/tlcr-22-106

Ejemplares similares